Tjoapack has signed an agreement to supply packaging for Photocure’s bladder cancer detection products.
Under the five-year-deal, Tjoapack will handle the secondary packaging and assembly of product kits for supply to 25 European countries, as well as the US, Canada, and Australia.
Headquartered in Norway, Photocure developed the Hexvix/Cysview drug that helps in the detection of cancerous tumours in the bladder.
Once cancer cells are exposed to the drug, they glow bright pink during blue light cystoscopy (BLCTM), enabling improved detection and management decisions.
Tjoapack corporate strategy director Dexter Tjoa said: “Photocure has a global customer base, which comes with many potential challenges. At Tjoapack, we have a huge amount of experience in meeting the demands of multiple markets, especially when it comes to complying with legislation such as artwork requirements and serialisation.
“In addition, the flexibility offered by our on-site warehousing facility will allow us to ensure continued supply in the shortest possible lead-times. We hope this will be the start of a long and successful partnership.”
During the contract period, Tjoapack will work with semi-finished stock stored at its facility.
The company will only finalise and assemble kits as and when it receives orders.
Photocure technical development and operations vice-president Gry Stensrud said: “We were also specifically looking for a supplier who was ready for serialisation.
“While our product does not need to be serialised in the US as imaging drugs are exempt there, compliance with the EU FMD is vital in order to ensure continuous supply to our European markets.”
Established in 1989, Tjoapack is an experienced provider of primary packaging for solid dosage forms, secondary packaging, and unit dose packaging, as well as serialisation.
The company operates a total of 19 packaging lines, including blisters, wallets, and bottle types.